Development of anti-CD20 therapy for multiple sclerosis

Treatment of multiple sclerosis with anti-CD20 antibodies.

The recently successful targeting of B cells in patients with multiple sclerosis (MS) using monoclonal antibodies (mAbs) targeting CD20 has established that it is no longer a question of whether B cells contribute, but how they contribute, to MS disease activity. Here, the focus will be to review results that have emerged over the last few years from clinical trials of different anti-CD20 mAbs ...

Anti-Integrin Therapy for Multiple Sclerosis

Integrins are the foremost family of cell adhesion molecules that regulate immune cell trafficking in health and diseases. Integrin alpha4 mediates organ-specific migration of immune cells to the inflamed brain, thereby playing the critical role in the pathogenesis of multiple sclerosis. Anti-alpha4 integrin therapy aiming to block infiltration of autoreactive lymphocytes to the inflamed brain ...

Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill

Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech, and Biogen) in neuroimmunological diseases, ocrelizumab (OCR; Ocrevus, Genentech) was developed as a treatment option for MS and selectively targets CD20 B cells, a cell surface antigen found on pre-B cells, mature, and mem...

mesenchymal stem cell therapy for multiple sclerosis

human mesenchymal stem cell (msc) can be isolated from bone marrow (bm) and differentiated into multiple lineages. these properties make them promising tools in cell and gene therapy. up to now, no definite therapeutic intervention for late stages of multiple sclerosis (ms) has been found. we decided to inject ms patients with autologous expanded msc. five patients participated in this ongoing ...